A drug nearing regulatory approval, daraxonrasib, is the first to substantially extend the lives of patients with pancreatic cancer.
-
A drug nearing regulatory approval, daraxonrasib, is the first to substantially extend the lives of patients with pancreatic cancer. It works by targeting a cellular protein that fuels not just nearly all pancreatic tumors, but also many lung and colon cancers. Those three are the leading causes of cancer deaths.
#science #pathology #pharmacetucals #medicine #healthcare #oncology
https://www.nytimes.com/2026/05/12/health/pancreatic-cancer-daraxonrasib-kras.html -
T #medicine shared this topic
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better đź’—
Register Login